Accelerate Diagnostics, Inc. (NASDAQ:AXDX) an in vitro diagnostics unit, is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.33 per share.
Looking ahead, the full year loss are expected at $ 1.39 per share on the revenues of $ 12.00 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 16.00 million ~ $ 18.00 million
Click Here For More Historical Outlooks Of Accelerate Diagnostics, Inc.
Previous Quarter Performance
Accelerate Diagnostics, Inc. unveiled loss for the second quarter of $ 0.35 per share, from the revenue of $ 2.12 million. The quarterly revenues elevated 17.13 percent compared with the same quarter last year. Street analysts expected Accelerate Diagnostics, Inc. to report loss of $ 0.34 per share on revenue of $ 2.46 million for the second quarter. The bottom line results missed street analysts by $ 0.01 or 2.94 percent, at the same time, top line results fell short of analysts by $ 0.34 million or 13.82 percent.
Stock Performance
Shares of Accelerate Diagnostics, Inc. traded up $ 0.11 or 1.13 percent on Wednesday, reaching $ 9.82 with volume of 176.30 thousand shares. Accelerate Diagnostics, Inc. has traded high as $ 10.39 and has cracked $ 9.63 on the downward trend
The closing price of $ 9.82, representing a 114.35 % increase from the 52 week low of $ 4.53 and a 49.19 % decrease over the 52 week high of $ 19.11.
The company has a market capital of $ 553.41 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Accelerate Diagnostics, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website acceleratediagnostics.com
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc.
